IP Library Granted Patent US 7,655,233
Granted Patent B2
US 7,655,233 · App. 11/274,812 · Granted Feb 2, 2010

Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin

Assignee: Ortho-Clinical Diagnostics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,655,233
App. No.
11/274,812
Granted
Feb 2, 2010
Kind
B2
Abstract

The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs.

Claims (13)

1. A method of virus inactivation in a post-manufacture immunoglobulin solution comprising:

reducing the potential virus load of the immunoglobulin solution,

adjusting the protein concentration of the immunoglobulin solution to equal or less than 6.0% w/v,

adjusting the pH of the immunoglobulin solution to 6.3-6.4,

contacting the immunoglobulin solution with 0.03% to 0.06% w/v of a di- or tri-alkyl phosphate solvent and 0.1% to less than 0.2% w/v of a non-ionic detergent for about 1 minute to about 1 hour at a temperature of 15-25° C.

2. The method of claim 1 wherein the immunoglobulin is anti-D immunoglobulin.

3. The method of claim 2 wherein the di- or tri-alkyl phosphate is tri-n-butyl-phosphate and the non-ionic detergent is an oxyethylated alkylphenol.

4. The method of claim 3 wherein the oxyethylated alkylphenol is a Triton®.

5. The method of claim 4 wherein the immunoglobulin solution is contacted with di- or tri-alkyl phosphate is present at 0.06% w/v and the non-ionic detergent is present at 0.2% w/v.

6. The method of claim 1 additionally comprising the step of removing the solvent and detergent from the immunoglobulin solution by a method selected from passage through a C-18 column, diafiltration through membranes, adsorption onto chromatographic supports, adsorption onto affinity chromatographic supports, ultrafiltration, filtration and adsorption, and admixture with adsorbent.

7. The method of claim 6 wherein the method is admixture with adsorbent.

8. The method of claim 7 wherein the adsorbent is a silica bead adsorbent material.

9. The method of claim 8 additionally comprising the step of removing the adsorbent from the immunoglobulin solution.

Assignments (4)
CHANGE OF NAME Recorded Jan 15, 2016
From: KEDRION MELVILLE INC.
To: KEDRION BIOPHARMA INC.
Reel/Frame 037542/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2012
From: ORTHO-CLINICAL DIAGNOSTICS, INC., AN AFFILIATE OF JOHNSON & JOHNSON
To: GIANT II NEWCO, INC.
Reel/Frame 029098/0973 →
CHANGE OF NAME Recorded Oct 9, 2012
From: GIANT II NEWCO, INC.
To: KEDRION MELVILLE INC.
Reel/Frame 029101/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2006
From: VAN HOLTEN, MR. ROBERT W.; AUTENRIETH, MR. STEPHEN M.
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 018043/0111 →
Continuity (1)
Related Publication 20060110399A1 · May 25, 2006